MRI and ARIA monitoring still shape at-home Leqembi decisions in 2026. People with early Alzheimer's can now begin treatment at home, but brain-scan follow-up and side-effect checks remain part of continued use.
Leqembi is lecanemab, an anti-amyloid drug for early Alzheimer's. ARIA means amyloid-related imaging abnormalities, swelling or bleeding changes seen on MRI during treatment. According to the Alzheimer's Drug Discovery Foundation, the FDA approved once-weekly subcutaneous Leqembi Iqlik as a starting dose on July 13, 2026, allowing home use with an autoinjector rather than IV infusions Foundation statement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does at-home starting actually change?
- Do you still need MRIs?
- What are ARIA-E and ARIA-H?
- Who should revisit risk before continuing?
- When should you pause and call?
- Frequently Asked Questions
What does at-home starting actually change?
Home starting changes where the drug enters the body, not whether monitoring matters. The approved initiation regimen is 500 mg weekly as two consecutive 250-mg autoinjector injections of about 15 seconds each, dropping to 360 mg weekly after 18 months, as reported by Alzheimer's News Today availability report.
That routine replaces biweekly infusion visits for dosing. It does not replace brain checks, symptom review, or continuation decisions. Families should plan for travel to imaging and clinic visits even while injections happen at home.
Do you still need MRIs?
Yes. Follow-up visits continue during at-home use because prescribers use symptoms plus MRI severity to decide whether to continue, pause, or stop Leqembi.
Enhanced vigilance is especially important during the first 14 weeks. For IV treatment, the FDA recommends a baseline MRI within one year plus scans before the 3rd, 5th, 7th and 14th infusions. That schedule reflects an August 28, 2025 safety communication that added an earlier MRI between the second and third infusions FDA safety communication.
What are ARIA-E and ARIA-H?
ARIA-E is brain edema or sulcal effusion, meaning swelling or fluid buildup. ARIA-H is microhemorrhage or superficial siderosis, meaning small bleeds or iron deposits from bleeding.
Both usually occur early and are often asymptomatic. They can still cause headache, confusion, seizure, status epilepticus or death. Report these signs promptly rather than waiting for the next injection day:.
- New or worse headache
- Confusion, trouble thinking, or behavior change
- Seizure or seizure-like episode
- Sudden weakness, vision change, or severe nausea
Who should revisit risk before continuing?
People with two copies of ApoE ε4 face higher severe radiographic ARIA rates on Leqembi. Reported rates are 5% for ARIA-E and 13.5% for ARIA-H versus near-zero in noncarriers.
FDA labeling urges ApoE testing and counseling before treatment. If testing was skipped, results were unclear, or family history suggests higher risk, revisit testing and consent. A homozygote result does not automatically forbid treatment, but it changes the monitoring conversation.
When should you pause and call?
Treat missed MRIs and new symptoms as reasons to revisit continuation. Home dosing should not be assumed lower-risk because it was approved on IV efficacy plus pharmacokinetic equivalence and similar amyloid clearance, not a dedicated clinical-outcomes trial.
Call the prescribing team before the next home dose when an MRI was missed, a scan showed ARIA, symptoms appeared, or another illness or fall complicated care. Bring the injection dates, symptom onset, ApoE result, and most recent MRI report. Do not restart after a pause until the team reviews severity and timing.
Frequently Asked Questions
Can treatment start at home without prior IV Leqembi?
Yes, the 2026 starting-dose approval allows eligible patients to begin with weekly subcutaneous injections rather than starting with IV infusions.
Does a normal early MRI mean later scans are unnecessary?
No. ARIA risk is highest early but management depends on both symptoms and MRI severity over time, so follow the prescribed scan and visit plan.
What should caregivers track between visits?
Injection dates, missed doses, headaches, confusion, seizures, falls, new medicines, and MRI appointments and results.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Follow-Up Decisions People With Early Alzheimer’s May Need to Revisit
- Cross-Cultural Dementia Risk Programs After LatAm-FINGERS 2026: How the Advice Compares With Common Online Claims for Adults in Midlife
- The Long-Term Care Data Cooperative and Dementia Research in 2026: Questions People With Mild Cognitive Impairment Can Ask About the Research
